VivoSeq
Other

Antiretroviral Treatment

0

Pipeline Programs

6

Active Trials

6

Companies Involved

Antiretroviral Treatment is an early-stage landscape with 0 programs across 6 companies. The most active players are Gilead, Johnson & Johnson, Tobira Therapeutics, Inc..

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

10/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

49

clinical trials

Completed33 · 67%
Unknown status5 · 10%
Active, not recruiting3 · 6%
Terminated3 · 6%
Not yet recruiting2 · 4%
Withdrawn2 · 4%
Other1 · 2%

Trial Activity

49 trials

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
Active, not recruiting·Merck & Co. logoMerck & Co.·Phase 3·NCT05705349·537 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)